Last reviewed · How we verify

BETIBEGLOGENE AUTOTEMCEL — Competitive Intelligence Brief

BETIBEGLOGENE AUTOTEMCEL (BETIBEGLOGENE AUTOTEMCEL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed β-globin gene Gene therapy Live · refreshed every 30 min

Target snapshot

BETIBEGLOGENE AUTOTEMCEL (BETIBEGLOGENE AUTOTEMCEL). ZYNTEGLO adds functional β-globin genes to patient HSCs, producing RBCs with modified β A-T87Q -globin to correct β/α-globin imbalance and increase Hb levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BETIBEGLOGENE AUTOTEMCEL TARGET BETIBEGLOGENE AUTOTEMCEL marketed β-globin gene 2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BETIBEGLOGENE AUTOTEMCEL — Competitive Intelligence Brief. https://druglandscape.com/ci/betibeglogene-autotemcel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: